Illumina

Sequencing Buyers’ Guide

Get past the hype and bias in sequencing vendor marketing materials, and get an unbiased, highly informed view from a highly qualified professional whose job it is to evaluate sequencing technologies for a world leading healthcare and research institution – the Mayo Clinic. Get a base- to high-level understanding of the sequencing process, to give […]

Illumina and Pacific Biosciences Announce Termination of their $1.2 billion Merger Deal

Illumina, Inc. (Illumina) and Pacific Biosciences of California, Inc. (PacBio) announced that they have mutually agreed to terminate their merger agreement. The merger was first proposed in November 2018 that Illumina would be acquiring PacBio at a fully diluted enterprise value of ~$1.2 billion. Now with the merger terminated, Illumina will have to pay a termination fee of $98 million to PacBio.

Illumina’s $1.2 Billion PacBio Takeover Threatened by CMA Concerns

The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.

Illumina Buys PacBio for $1.2bn

DNA sequencing company Pacific Biosciences (PacBio) is being bought for $1.2bn by bigger rival Illumina, it was announced yesterday. The deal represents a 71% premium on yesterday’s closing price for PacBio, and is the largest that Illumina has ever made.